Leptin, acylcarnitine metabolites, and development of adiposity in the Rhea Mother-Child Cohort in Crete, Greece

Wei Perng,[1] Emily Oken,[2,3] Theano Roumeliotaki,[4] Deepti Sood,[5] Alexandros P. Siskos,[5] Georgia Chalkiadaki,[4] Eirini Dermitzaki,[6] Marina Vafeiadi,[4] Soterios Kyrtopoulos,[7] Manolis Kogevinas,[8] Hector C. Keun,[5] and Leda Chatzi[4]

[1] Department of Nutritional Sciences, University of Michigan School of Public Health, MI, USA.
[2] Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA, USA.
[3] Department of Nutrition, T.H. Chan Harvard School of Public Health, Boston, MA, USA.
[4] Department of Social Medicine, Faculty of Medicine University of Crete, Heraklion, Greece
[5] Department of Surgery & Cancer, Faculty of Medicine, Imperial College, London
[6] Lab of Clinical Chemistry-Biochemistry, Department of Laboratory Medicine, School of Medicine, University of Crete, Heraklion, Crete, Greece
[7] National Hellenic Research Foundation, Institute of Biology, Medicinal Chemistry and Biotechnology, Athens, Greece
[8] Center for Environmental Research, CREAL, Barcelona, Spain.

Correspondence: Wei Perng
Department Nutritional Sciences
University of Michigan School of Public Health
Ann Arbor, MI, USA
E-mail: perngwei@umich.edu

Conflicts of interest: None

Word count: 1526
Tables: 2
Figures: 0
References: 28
Supplemental Files: 1

Key words: leptin, adiposity, children, targeted metabolomics, acylcarnitine metabolites

Abbreviations: BMIZ: body mass index-for-age-z-score; HAZ: height-for-age z-score; SS: subscapular skin fold, TR: triceps skinfold

ABSTRACT

Objective: (1) To investigate relations of serum leptin at age 4 with development of adiposity and linear growth during 3 years of follow-up among 75 Greek children; (2) to identify serum metabolites associated with leptin at age 4 and to characterize their associations with adiposity gain and linear growth.

Methods: Linear regression models that accounted for maternal age, education, and gestational weight gain; and child's age and sex were used to examine associations of leptin and leptin-associated metabolites measured at age 4 with indicators of adiposity and linear growth at age 7.

Results: Each 1-unit increment in natural log-(ln)-transformed leptin corresponded with 0.33 (95% CI: 0.10, 0.55) units greater body mass index z-score (BMIZ) gain during follow-up. Likewise, higher levels of the leptin-associated metabolites methylmalonyl-carnitine and glutaconyl-carnitine corresponded with 0.14 (95% CI: 0.01, 0.27) and 0.07 (95% CI: -0.01, 0.16) units higher BMIZ gain, respectively. These relationships did not differ by sex or baseline weight status, and were independent of linear growth.

Conclusions: These findings suggest that leptin, methylmalonyl-carnitine, and possibly glutaconyl-carnitine are associated with weight gain during early childhood. Future studies are warranted to confirm these findings in other populations.

INTRODUCTION

Leptin, an adipocyte-derived hormone, is an important regulator of weight and metabolism. Although high circulating leptin is traditionally regarded as a consequence of excess fat mass, elevated leptin can also precede weight gain. In adults, high leptin in conjunction with overweight/obesity status suggests hypothalamic resistance to leptin's hunger-inhibiting effects,[1] which could lead to additional weight gain over time. Several studies have also observed a direct relationship between circulating leptin and subsequent weight gain after adjusting for body size at baseline,[2-4] suggesting that leptin resistance can occur independently of weight status. This relationship is less clear in children. Studies in pediatric populations indicate that both low[5, 6] and high [7-9] leptin are associated with weight gain over time. Potential explanations for the discrepancies include the possibility that young children may not yet have developed leptin resistance,[10] and the fact that leptin has pleiotropic effects on bone growth,[11] which could confound the relationship between leptin and adiposity gain.

The overarching aim of this study was to investigate relations of serum leptin at age 4 years with adiposity gain and linear growth during 3 years of follow-up among 75 children. To improve understanding of biochemical pathways linking leptin to weight gain, a secondary aim was to identify metabolites associated with leptin at baseline and to explore their relations with adiposity and linear growth during follow-up.

Our hypothesis was that higher leptin, as well as any leptin-related metabolites, is associated with greater gains in adiposity, as indicated by change in age- and sex-standardized

4

body mass index (BMI), the sum of the triceps and subscapular skinfold thicknesses, % fat mass, and waist circumference, independently of linear growth. Results from this work will enhance understanding of etiological pathways underlying the accrual of excess fat mass during early life.

5

METHODS

This study includes participants of the Rhea Cohort in Crete, Greece.[12] The present analysis included 75 children with data on anthropometry, serum leptin, and targeted metabolomics data at the 4-year research visit (baseline), and anthropometry at the 7-year visit (follow-up). All procedures were approved by the ethics committee of the University Hospital in Heraklion, Crete, Greece. All participants provided written informed consent.

Anthropometry

At the 4-year visit, research assistants (RAs) measured the children's weight, height, waist circumference, and the subscapular (SS) and triceps (TR) skinfold thicknesses.[13] Body mass index-for-age (BMIZ) and height-for-age z-scores (HAZ) were derived using the World Health Organization growth standard.[14-16] Indicators of adiposity included BMIZ, SS+TR, % fat calculated from skinfolds using Slaughter's equation,[17] and waist circumference. At the 7-year visit, RAs measured anthropometry and calculated the same anthropometric indices. At this time, RAs also conducted bioelectrical impedance assessments (BIA) of fat mass and % fat. Outcomes of interest were change in each adiposity indicator (BMIZ, SS+TR, Slaughter's % fat, waist circumference) and linear growth (HAZ) between the 4-year and 7-year visits. Attained BIA fat mass and % fat at 7 years were also assessed, although it was not possible to calculate change as BIA was only carried out at follow-up.

6

Serum leptin & targeted metabolomics

At the 4-year visit, RAs collected blood from the children, from which serum leptin (ng/mL) was quantified.[18] Targeted metabolomics analyses were carried out on serum to quantify amino acid and acylcarnitine species previously associated with childhood obesity and leptin[19] using a mass spectrometry-based approach (Absolute IDQ p180 kit, Biocrates Life Sciences AG, Austria). Metabolite concentrations were adjusted for batch effects and normalized as a z-score centered on the median and scaled by the mean absolute deviation from the median.

Data analysis

The first step of the analysis was to examine associations of leptin with background characteristics in order to identify potential confounders. Owing to non-normal distributions, leptin was natural log-(ln)-transformed prior to regression analysis. The next step was to estimate change in each adiposity indicator and HAZ with respect to quartiles of leptin using linear regression. The associations were linear, so leptin was evaluated continuously. In multivariable analysis, the models accounted for maternal age, education, and gestational weight gain,[20] and child's age at the 4-year and 7-year assessments, and sex. In all models for the adiposity outcomes, HAZ change was also included as a covariate.

To identify metabolites associated with leptin, linear regression models with leptin as the independent variable, age and sex as covariates, and individual metabolite z-scores as the outcome were used. Metabolites were retained for further analyses if the *P*-value for leptin's β

was <0.05. Next, relations of each leptin-associated metabolite with change in the anthropometric outcomes were assessed using the same approach as for leptin.

In sensitivity analyses, maternal pre-pregnancy BMI, birthweight-for-gestational-age, and breastfeeding duration were included in the models; accounting for these covariates did not change the results; thus they were not included in the final models. Formal tests for statistical interactions with sex and baseline weight status were carried out for all associations. All analyses were performed using SAS 9.3 (Cary, NC, USA).

8

RESULTS

Median age at baseline was 4.2 years (range 4.0–4.5); 57.3% were boys. **Table 1** shows associations of leptin with background characteristics. All adiposity indicators and HAZ were positively related to leptin at baseline.

In multivariable analysis, each increment in ln-leptin corresponded with 0.33 (95% CI: 0.10, 0.55) units greater BMIZ gain during follow-up. Similar associations were observed for the other adiposity indicators, although the confidence intervals contained the null. Leptin at 4 years was positively associated with BIA fat mass and % fat at 7 years (**Table 2**).

Of the 21 amino acids and 20 acylcarnitines quantified from serum at the 4-year visit, two were associated with leptin: glutanconyl-carnitine and methylmalonyl-carnitine (**Supplemental Table 1**); both were positively associated with BMIZ gain, as well as BIA fat mass and % fat at 7 years (**Table 2**). Neither leptin nor the metabolites were related to linear growth. Adjustment for HAZ change in models for the adiposity outcomes attenuated effect sizes, although the relations with BMIZ remained apparent. There was no evidence of effect modification by sex or baseline weight status.

9

DISCUSSION

In this study of Greek children, higher leptin at age 4 was associated with greater BMIZ gain during 3 years of follow-up. Higher concentrations of the leptin-associated metabolites methylmalonyl-carnitine and glutaconyl-carnitine at baseline also corresponded with greater BMIZ gain. These relations did not differ by sex or baseline weight status, and were independent of linear growth.

Our results add to current evidence in several ways. First, most pediatric investigations of leptin and weight gain were conducted in older children (>6 years at baseline) and have yielded both positive[7-10] and inverse associations.[5, 6] The discrepant literature could be due to the influence of pubertal onset on the relation between leptin and body composition.[21] The positive association observed between leptin and BMIZ gain aligns with results from similarly-aged children in the U.S.,[10] and suggests that leptin resistance may begin early in the life course. Identification of specific timeframes and opportunities to mitigate leptin resistance is an area of ongoing human[10] and animal research.[22, 23]

Second, the relation between leptin and BMIZ gain was independent of HAZ change, suggesting that leptin stimulates fat accretion rather than linear growth during early childhood. However, because leptin was not associated with change in the other adiposity indicators, the relation with BMIZ may also reflect gains in lean mass that was not accounted for by height change. Future studies assessing change in directly-measured body composition (e.g. dual x-ray absorptiometry) are warranted to confirm our findings.

Finally, despite the established link between leptin and obesity,[1] little is known of the underlying biochemical pathways. Two leptin-associated metabolites were identified in the analysis, methylmalonyl-carnitine and glutaconyl-carnitine, both of which also correlated with BMIZ gain. Although the literature on glutaconyl-carnitine is scant, elevated methylmalonyl-carnitine is a hallmark of methylmalonic acidemia, a genetic defect in metabolism of certain fats and proteins.[24] Because leptin is involved in hepatic lipid oxidation,[25] the relationships among leptin, methylmalonyl-carnitine, and adiposity gain may revolve around altered fatty acid metabolism. Specifically, leptin resistance may lead to defective hepatic lipid oxidation, which can lead to dysregulated satiety[26] and weight gain.[27] In this scenario, methylmalonyl-carnitine is a marker of defective fatty acid metabolism rather than a causal mechanism; whether methylmalonyl-carnitine exerts independent pro-adipogenic effects deserves further investigation.

Strengths of this study include the prospective design, availability of blood specimens during early childhood, and added mechanistic insight via targeted metabolomics data. Limitations include the non-fasting nature of the blood draws, and the relatively small sample size.

In conclusion, higher leptin, methylmalonyl-carnitine, and glutaconyl-carnitine at age 4 corresponded with greater BMIZ gain between age 4 and 7 years, and higher BIA fat mass at 7 years. The magnitude of associations, particularly for leptin (0.33 higher BMIZ per unit ln-leptin), may have implications at the population level. In a large retrospective study of Danish

adults, each unit of BMIZ at age 7 corresponded with 10% and 7% higher risk of fatal

cardiovascular disease in males and females, respectively.[28] The risk increased linearly with age

such that it was twice as high by 13 years,[28] emphasizing the importance of identifying

determinants of excess weight gain as early as possible. Additional work is required to confirm

our findings and to identify modifiable determinants of leptin during early life.

ACKNOWLEDGEMENTS

REFERENCES

[1] Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. *Am J Physiol Endocrinol Metab*. 2011;**301**:E567-84.

[2] Chessler SD, Fujimoto WY, Shofer JB, Boyko EJ, Weigle DS. Increased plasma leptin levels are associated with fat accumulation in Japanese Americans. *Diabetes*. 1998;**47**:239-43.

[3] Chu NF, Spiegelman D, Yu J, Rifai N, Hotamisligil GS, Rimm EB. Plasma leptin concentrations and four-year weight gain among US men. *Int J Obes Relat Metab Disord*. 2001;**25**:346-53.

[4] Lissner L, Karlsson C, Lindroos AK, et al. Birth weight, adulthood BMI, and subsequent weight gain in relation to leptin levels in Swedish women. *Obes Res*. 1999;**7**:150-4.

[5] Ahmed ML, Ong KK, Morrell DJ, et al. Longitudinal study of leptin concentrations during puberty: sex differences and relationship to changes in body composition. *J Clin Endocrinol Metab*. 1999;**84**:899-905.

[6] Byrnes SE, Baur LA, Bermingham M, Brock K, Steinbeck K. Leptin and total cholesterol are predictors of weight gain in pre-pubertal children. *Int J Obes Relat Metab Disord*. 1999;**23**:146-50.

[7] Fleisch AF, Agarwal N, Roberts MD, et al. Influence of serum leptin on weight and body fat growth in children at high risk for adult obesity. *J Clin Endocrinol Metab*. 2007;**92**:948-54.

[8] Johnson MS, Huang TT, Figueroa-Colon R, Dwyer JH, Goran MI. Influence of leptin on changes in body fat during growth in African American and white children. *Obes Res*. 2001;**9**:593-8.

[9] Savoye M, Dziura J, Castle J, DiPietro L, Tamborlane WV, Caprio S. Importance of plasma leptin in predicting future weight gain in obese children: a two-and-a-half-year longitudinal study. *Int J Obes Relat Metab Disord*. 2002;**26**:942-6.

[10] Boeke CE, Mantzoros CS, Hughes MD, et al. Differential associations of leptin with adiposity across early childhood. *Obesity (Silver Spring)*. 2013;**21**:1430-7.

[11] Gat-Yablonski G, Phillip M. Leptin and regulation of linear growth. *Curr Opin Clin Nutr Metab Care*. 2008;**11**:303-8.

[12] Chatzi L, Plana E, Daraki V, et al. Metabolic syndrome in early pregnancy and risk of preterm birth. *Am J Epidemiol*. 2009;**170**:829-36.

[13] Vafeiadi M, Georgiou V, Chalkiadaki G, et al. Association of Prenatal Exposure to Persistent Organic Pollutants with Obesity and Cardiometabolic Traits in Early Childhood: The Rhea Mother-Child Cohort (Crete, Greece). *Environ Health Perspect*. 2015.

[14] de Onis M, Onyango AW, Borghi E, Siyam A, Nishida C, Siekmann J. Development of a WHO growth reference for school-aged children and adolescents. *Bull World Health Organ*. 2007;**85**:660-7.

[15] World Health Organizaton. WHO child growth standards: height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index for-age: methods and development. Geneva, Switzerland: World Health Organizaton; 2006.

[16] de Onis M, Garza C, Victora C, Bhan M, Norum K. The WHO Multicentre Growth Reference Study (MGRS): rationale, planning, and implementaton. *Food Nutr Bull*. 2004;**25**:S1-S89.

[17] Slaughter MH, Lohman TG, Boileau RA, et al. Skinfold equations for estimation of body fatness in children and youth. *Hum Biol*. 1988;**60**:709-23.

[18] Karakosta P, Georgiou V, Fthenou E, et al. Maternal Weight Status, Cord Blood Leptin and Fetal Growth: a Prospective Mother–Child Cohort Study (Rhea Study). *Paediatric and Perinatal Epidemiology*. 2013;**27**:461-71.

[19] Perng W, Gillman MW, Fleisch AF, et al. Metabolomic profiles and childhood obesity. *Obesity (Silver Spring)*. 2014;**22**:2570-8.

[20] Institute of Medicine National Research Council Committee to Reexamine I. O. M. Pregnancy Weight Guidelines. The National Academies Collection: Reports funded by National Institutes of Health. In: Rasmussen KM, Yaktine AL, editors. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington (DC): National Academies Press (US) National Academy of Sciences; 2009.

[21] Horlick MB, Rosenbaum M, Nicolson M, et al. Effect of puberty on the relationship between circulating leptin and body composition. *J Clin Endocrinol Metab*. 2000;**85**:2509-18.

[22] Vickers MH, Gluckman PD, Coveny AH, et al. Neonatal leptin treatment reverses developmental programming. *Endocrinology*. 2005;**146**:4211-6.

[23] Krechowec SO, Vickers M, Gertler A, Breier BH. Prenatal influences on leptin sensitivity and susceptibility to diet-induced obesity. *J Endocrinol*. 2006;**189**:355-63.

[24] Maeda Y, Ito T, Suzuki A, et al. Simultaneous quantification of acylcarnitine isomers containing dicarboxylic acylcarnitines in human serum and urine by high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. *Rapid Commun Mass Spectrom*. 2007;**21**:799-806.

[25] Wein S, Ukropec J, Gasperikova D, Klimes I, Sebokova E. Concerted action of leptin in regulation of fatty acid oxidation in skeletal muscle and liver. *Exp Clin Endocrinol Diabetes*. 2007;**115**:244-51.

[26] Ronnett GV, Kleman AM, Kim EK, Landree LE, Tu Y. Fatty acid metabolism, the central nervous system, and feeding. *Obesity (Silver Spring)*. 2006;**14 Suppl 5**:201s-7s.

[27] Vijayakumar RS, Lin Y, Shia KS, et al. Induction of fatty acid oxidation resists weight gain, ameliorates hepatic steatosis and reduces cardiometabolic risk factors. *Int J Obes (Lond)*. 2012;**36**:999-1006.

[28] Baker JL, Olsen LW, Sorensen TI. Childhood body-mass index and the risk of coronary heart disease in adulthood. *N Engl J Med*. 2007;**357**:2329-37.

Table 1 Distribution of serum leptin concentrations at baseline (4 years) according to characteristics of 75 Rhea cohort mother-child pairs

	N^a	Mean ± SD Leptin (ng/mL)	P^b
Overall	75	2.34 ± 1.49	
Family and perinatal characteristics			
Mother's age at enrollment			0.23
20-24 years	4	2.08 ± 1.06	
25-34 years	55	2.20 ± 1.43	
35-43 years	14	2.73 ± 1.60	
Mother's education			0.82
Less than univeristy	33	2.41 ± 1.80	
University education	40	2.33 ± 1.22	
Parity			0.91
Primiparous	30	2.33 ± 1.27	
Muliparous	37	2.29 ± 1.61	
Mother's pre-pregnancy BMI			0.16
Normal weight (18.5-24.9 kg/m^2)	51	2.05 ± 1.11	
Overweight (25-29.9 kg/m^2)	15	3.35 ± 2.18	
Obese (≥30 kg/m^2)	6	1.89 ± 0.31	
Gestational weight gain[c]			0.13
Inadequate	16	2.43 ± 1.61	
Adequate	33	2.60 ± 1.59	
Excessive	23	1.81 ± 0.99	
Birth size[d]			0.94
SGA (<10th %tile)	6	2.36 ± 2.59	
AGA (10 -≤ 90th %tile)	63	2.33 ± 1.40	
LGA (>90th %tile)	6	2.43 ± 1.33	
Mother smoking habits			0.38
Never	49	2.47 ± 1.63	
Former	12	1.84 ± 0.86	
Smoked during pregnancy	8	2.18 ± 1.11	
Duration of breastfeeding			0.82
<6 months	55	1.27 ± 1.42	
≥6 months	20	2.28 ± 1.60	
Child characteristics at the 4-year research visit			
Sex			0.03
Female	32	2.77 ± 1.79	
Male	43	2.02 ± 1.14	
BMI-for-age z-score[e]			0.0002
≤ 1	46	1.89 ± 1.14	
>1 and ≤ 2	15	2.72 ± 1.57	
>2	14	3.41 ± 1.85	

Table 1 (continued) Distribution of serum leptin concentrations at baseline (4 years) according to characteristics of 75 Rhea cohort mother-child pairs

	N^a	Mean ± SD Leptin (ng/mL)	P^b
Child characteristics at the 4-year research visit			
SS+TR (mm)			<0.0001
Tertile 1 (median = 12.5)	23	1.38 ± 0.68	
Tertile 2 (median = 16.5)	24	2.30 ± 1.06	
Tertile 3 (median = 21.4)	24	3.39 ± 1.84	
Slaughter's % fat			<0.0001
Tertile 1 (median = 13.5)	23	1.33 ± 0.64	
Tertile 2 (median = 19.0)	24	2.34 ± 1.04	
Tertile 3 (median = 24.6)	24	3.39 ± 1.84	
Waist circumference (cm)			<0.0001
Tertile 1 (median = 50.0)	24	1.40 ± 0.72	
Tertile 2 (median = 53.5)	24	2.35 ± 1.19	
Tertile 3 (median = 57.2)	26	3.25 ± 1.74	
Height-for-age z-score[e]			0.007
≤ 1	59	2.17 ± 1.30	
>1 and ≤ 2	13	2.60 ± 1.38	
>2	3	4.69 ± 3.46	

a Totals may not add up to 75 due to missing values.
b Represents a test for linear trend with the exception of sex, smoking habits, and breastfeeding duration (Wald test).
c According the IOM 2009 gestational weight gain guidelines.[12]
d Based on internally-standardized percentile values as previously described.[4]
e According to the World Health Organization growth reference.[6-8] For both BMI and height, the "<1 z-score" category includes one child with z-score <-2.

Table 2 Associations of leptin and two leptin-associated metabolites with adiposity and linear growth during follow-up

	Mean ± SD	β (95% CI) for change in each anthropometric indicator		
		Leptin *per unit*[a]	Methylmalonyl-carnitine *per z-score*[b]	Glutaconyl-carnitine *per z-score*[b]
Δ Adiposity (*7 years-4 years*)				
Δ BMI z-score	0.75 ± 0.92			
Model 1		**0.33 (0.10, 0.55)**	**0.14 (0.01, 0.27)**	0.07 (-0.01, 0.16)
Model 2		**0.25 (0.04, 0.45)**	**0.11 (0.00, 0.23)**	**0.09 (0.01, 0.16)**
Δ SS+TR (mm)	1.19 ± 6.59			
Model 1		1.41 (-0.33, 3.17)	0.49 (-0.53, 1.51)	0.08 (-0.59, 0.74)
Model 2		1.14 (-0.59, 2.88)	0.50 (-0.50, 1.49)	0.18 (-0.47, 0.83)
Δ Slaughter's % fat	-2.17 ± 5.15			
Model 1		0.28 (-1.14, 1.71)	0.19 (-0.64, 1.01)	0.04 (-0.49, 0.57)
Model 2		0.09 (-1.34, 1.51)	0.19 (-0.62, 1.00)	0.11 (-0.42, 0.63)
Δ Waist circumference (cm)	4.88 ± 4.87			
Model 1		0.72 (-0.54, 1.99)	-0.04 (-0.78, 0.70)	-0.23 (-0.71, 0.24)
Model 2		0.39 (-0.77, 1.55)	-0.05 (-0.71, 0.62)	-0.12 (-0.56, 0.31)
Linear growth (*7 years-4 years*)				
Δ Height z-score	0.29 ± 0.37	0.06 (-0.02, 0.14)	0.02 (-0.03, 0.07)	-0.01 (-0.04, 0.02)
BIA measurements at 7 years				
Fat mass (kg)	6.0 ± 3.0			
Model 1		**1.60 (0.85, 2.36)**	**0.52 (0.06, 0.98)**	0.28 (-0.02, 0.59)
Model 2		**1.45 (0.71, 2.18)**	**0.47 (0.02, 0.91)**	**0.32 (0.03, 0.61)**
% Fat	23.0 ± 6.6			
Model 1		**2.84 (1.09, 4.58)**	0.48 (-0.20, 1.17)	0.99 (-0.04, 2.02)
Model 2		**2.66 (0.91, 4.41)**	0.92 (-0.10, 1.94)	0.53 (-0.15, 1.20)

Model 1: adjusted for mother's age, education, and gestational weight gain (IOM 2009 categories); and child's age and sex.
Model 2: Model 1 + change in height z-score
a Natural log-(ln)-transformed for regression analysis
b Each metabolite was centered at the median and scaled by the mean absolute distance (MAD) from the median.